Several immunotherapeutic approaches have been developed targeting BCMA in multiple myeloma, including mAbs, T-cell bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapies, and antibody–drug conjugates (ADC). The gene discussed is TNFRSF17; the disease is AL amyloidosis.